HEC Pharma

HEC Pharma is a leading Chinese pharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic products across anti-virals, endocrine and metabolic diseases, and cardiovascular health. The company holds a dominant market position in China's anti-influenza segment with its flagship product Kewei (oseltamivir phosphate), which is available in both capsule and granule forms. Beyond its antiviral success, HEC Pharma has established a significant presence in the diabetes market through a comprehensive portfolio of insulin analogues and oral hypoglycemic agents. The company operates an integrated business model supported by large-scale GMP-certified manufacturing facilities and a robust R&D engine, primarily through its subsidiary Sunshine Lake Pharma.